Neuroscience Bulletin

, Volume 28, Issue 1, pp 39–48 | Cite as

Progression of motor symptoms in Parkinson’s disease

Review

Abstract

Parkinson’s disease (PD) is a chronic progressive neurodegenerative disease that is clinically manifested by a triad of cardinal motor symptoms — rigidity, bradykinesia and tremor — due to loss of dopaminergic neurons. The motor symptoms of PD become progressively worse as the disease advances. PD is also a heterogeneous disease since rigidity and bradykinesia are the major complaints in some patients whereas tremor is predominant in others. In recent years, many studies have investigated the progression of the hallmark symptoms over time, and the cardinal motor symptoms have different rates of progression, with the disease usually progressing faster in patients with rigidity and bradykinesia than in those with predominant tremor. The current treatment regime of dopamine-replacement therapy improves motor symptoms and alleviates disability. Increasing the dosage of dopaminergic medication is commonly used to combat the worsening symptoms. However, the drug-induced involuntary body movements and motor complications can significantly contribute to overall disability. Further, none of the currently-available therapies can slow or halt the disease progression. Significant research efforts have been directed towards developing neuroprotective or disease-modifying agents that are intended to slow the progression. In this article, the most recent clinical studies investigating disease progression and current progress on the development of disease-modifying drug trials are reviewed.

Keywords

Parkinson’s disease progression motor symptoms disease modification treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Poewe W. Clinical measures of progression in Parkinson’s disease. Mov Disord 2009, 24Suppl 2: S671–676.PubMedCrossRefGoogle Scholar
  2. [2]
    Poewe W, Mahlknecht P. The clinical progression of Parkinson’s disease. Parkinsonism Relat Disord 2009, 15Suppl 4: S28–32.PubMedCrossRefGoogle Scholar
  3. [3]
    Dorsey ER CR, Thompson JP, Biglan KM, Holloway RG. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68: 384–386.PubMedCrossRefGoogle Scholar
  4. [4]
    de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006, 5: 525–535.PubMedCrossRefGoogle Scholar
  5. [5]
    Lang AE, Lozano AM. Parkinson’s disease. Second of two parts. N Engl J Med 1998, 339: 1130–1143.PubMedCrossRefGoogle Scholar
  6. [6]
    Diaz NL, Waters CH. Current strategies in the treatment of Parkinson’s disease and a personalized approach to management. Expert Rev Neurother 2009, 9: 1781–1789.PubMedCrossRefGoogle Scholar
  7. [7]
    Stacy M. Medical treatment of Parkinson disease. Neurologic Clinics 2009, 27: 605–631.PubMedCrossRefGoogle Scholar
  8. [8]
    Hely MA, Morris JGL, Traficante R, Reid WGJ, O’sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999, 67: 300–307.PubMedCrossRefGoogle Scholar
  9. [9]
    Hely MA, Reid WGJ, Adena MA, Halliday GA, Morris JGL. The Sydney multicenter study of Parkinson’s disease: The inevitability of dementia at 20 years. Mov Disord 2008, 23: 837–844.PubMedCrossRefGoogle Scholar
  10. [10]
    Elias S, Israel Z, Bergman H. Physiology of Parkinson’s disease. In: Hallett M, Poewe W (Eds.) Therapeutics of Parkinson’s Disease and Other Movement Disorders. Chichester, UK: John Wiley & Sons, Ltd. 2008: 25–36.CrossRefGoogle Scholar
  11. [11]
    Hallett M. Parkinson revisited: Pathophysiology of motor signs. Adv Neurol 2003, 91: 19–28.PubMedGoogle Scholar
  12. [12]
    Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008, 70: 1403–1410.PubMedCrossRefGoogle Scholar
  13. [13]
    Rossi C, Frosini D, Volterrani D, De Feo P, Unti E, Nicoletti V, et al. Differences in nigro-striatal impairment in clinical variants of early Parkinson’s disease: evidence from a FP-CIT SPECT study. Eur J Neurol 2010, 17: 626–630.PubMedCrossRefGoogle Scholar
  14. [14]
    Chaudhuri KR, Naidu Y. Early Parkinson’s disease and non-motor issues. J Neurol 2008, 255 Suppl 5: 33–38.CrossRefGoogle Scholar
  15. [15]
    Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology 1986, 36: 1528–1530.PubMedGoogle Scholar
  16. [16]
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342: 1484–1491.PubMedCrossRefGoogle Scholar
  17. [17]
    Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 2000, 123( Pt 11): 2297–2305.PubMedCrossRefGoogle Scholar
  18. [18]
    The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993, 328: 176–183.CrossRefGoogle Scholar
  19. [19]
    The Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson’s disease. Ann Neurol 1996, 40: 99–107.CrossRefGoogle Scholar
  20. [20]
    Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004, 61: 561–566.CrossRefGoogle Scholar
  21. [21]
    Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin Neuropharmacol 2007, 30: 72–85.CrossRefGoogle Scholar
  22. [22]
    Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004, 351: 2498–2508.PubMedCrossRefGoogle Scholar
  23. [23]
    Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999, 56: 334–337.PubMedCrossRefGoogle Scholar
  24. [24]
    Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson’s disease: clinical and prognostic implications. Neurology 1985, 35: 522–526.PubMedGoogle Scholar
  25. [25]
    Fahn S, Elton RL, and members of the UPDRS development committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Jenner P, et al. (Eds.). Recent Developments in Parkinson’s Disease. New York: Macmillan, 1987: 153–164.Google Scholar
  26. [26]
    Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson’s disease rating scale. Mov Disord 2006, 21: 1200–1207.PubMedCrossRefGoogle Scholar
  27. [27]
    Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson’s disease rating scale. Arch Neurol 2010, 67: 64–70.PubMedCrossRefGoogle Scholar
  28. [28]
    Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990, 40: 1529–1534.Google Scholar
  29. [29]
    Schupbach WM, Corvol JC, Czernecki V, Djebara MB, Golmard JL, Agid Y, et al. Segmental progression of early untreated Parkinson’s disease: a novel approach to clinical rating. J Neurol Neurosurg Psychiatry 2010, 81: 20–25.PubMedCrossRefGoogle Scholar
  30. [30]
    Jellinger KA. Post mortem studies in Parkinson’s disease—is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999, 56: 1–29.PubMedGoogle Scholar
  31. [31]
    Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000, 15: 692–698.PubMedCrossRefGoogle Scholar
  32. [32]
    Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson’s disease: correlations with the three main symptoms. J Neurological Sci 1996, 136: 169–173.CrossRefGoogle Scholar
  33. [33]
    Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 2003, 18Suppl 7: S43–51.PubMedCrossRefGoogle Scholar
  34. [34]
    Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand [(18)F]_beta-CFT in assessing disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999, 67: 737–741.PubMedCrossRefGoogle Scholar
  35. [35]
    Brooks DJ, Playford ED, Ibanez V, Sawle GV, Thompson PD, Findley LJ, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology 1992, 42: 1554–1560.PubMedGoogle Scholar
  36. [36]
    Spiegel J, Dorschner J, Farmakis G, Behnke S, Hellwig D, Schneider S, et al. Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2011, 17: 372–375.PubMedCrossRefGoogle Scholar
  37. [37]
    Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson’s disease. J Nucl Med 1998, 39: 1143–1148.PubMedGoogle Scholar
  38. [38]
    Hoehn MM, Yahr MD. Parkinsonism — Onset Progression and Mortality. Neurology 1967, 17: 427–442.PubMedGoogle Scholar
  39. [39]
    Lee CS, Schulzer M, Mak EK, Snow BJ, Tsui JK, Calne S, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994, 117( Pt 3): 501–507.PubMedCrossRefGoogle Scholar
  40. [40]
    Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 2007, 22: 938–945.PubMedCrossRefGoogle Scholar
  41. [41]
    Duychaerts C, Greffard S, Verny M, Bonnet AM, Beinis JY, Gallinari C, et al. Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia Nigra. Arch Neurol 2006, 63: 584–588.CrossRefGoogle Scholar
  42. [42]
    Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5): 2283–2301.PubMedCrossRefGoogle Scholar
  43. [43]
    Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005, 62: 378–382.PubMedCrossRefGoogle Scholar
  44. [44]
    Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000, 69: 308–312.PubMedCrossRefGoogle Scholar
  45. [45]
    Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: A population-based, prospective study. J Am Geriatr Soc 2000, 48: 938–942.PubMedGoogle Scholar
  46. [46]
    Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006, 5: 235–245.PubMedCrossRefGoogle Scholar
  47. [47]
    Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoriola F, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006, 5: 572–577.PubMedCrossRefGoogle Scholar
  48. [48]
    Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 2008, 63: 167–173.PubMedCrossRefGoogle Scholar
  49. [49]
    Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP, et al. Identification of motor and nonmotor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005, 20: 726–733.PubMedCrossRefGoogle Scholar
  50. [50]
    Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ, Grp CS. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 2008, 70: 2241–2247.PubMedCrossRefGoogle Scholar
  51. [51]
    Gomez-Esteban JC, Zarranz JJ, Lezcano E, Tijero B, Luna A, Velasco F, et al. Influence of motor symptoms upon the quality of life of patients with Parkinson’s disease. Eur Neurol 2007, 57: 161–165.PubMedCrossRefGoogle Scholar
  52. [52]
    Lyons KE, Pahwa R, Troster AI, Koller WC. A comparison of Parkinson’s disease symptoms and self-reported functioning and well being. Parkinsonism Relat Disord 1997, 3: 207–209.PubMedCrossRefGoogle Scholar
  53. [53]
    Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009, 24: 1641–1649.PubMedCrossRefGoogle Scholar
  54. [54]
    Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Mac-Phee G, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007, 22: 1623–1629.PubMedCrossRefGoogle Scholar
  55. [55]
    Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M. Nonmotor versus motor symptoms: How much do they matter to health status in Parkinson’s disease? Mov Disord 2011. [Epub ahead of print]Google Scholar
  56. [56]
    Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 1997, 26: 353–357.PubMedCrossRefGoogle Scholar
  57. [57]
    Tan LC, Lau PN, Au WL, Luo N. Validation of PDQ-8 as an independent instrument in English and Chinese. J Neurol Sci 2007, 255: 77–80.PubMedCrossRefGoogle Scholar
  58. [58]
    Politis M, Wu K, Molloy S, G Bain P, Chaudhuri KR, Piccini P. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord 2010, 25: 1646–1651.PubMedCrossRefGoogle Scholar
  59. [59]
    Simuni T, Sethi K. Nonmotor manifestations of Parkinson’s disease. Ann Neurol 2008, 64 Suppl 2: S65–80.Google Scholar
  60. [60]
    Bassetti CL. Nonmotor disturbances in Parkinson’s disease. Neurodegener Dis 2011, 8: 95–108.PubMedCrossRefGoogle Scholar
  61. [61]
    Chan DT, Mok VC, Poon WS, Hung KN, Zhu XL. Surgical management of Parkinson’s disease: a critical review. Hong Kong Med J 2001, 7: 34–39.PubMedGoogle Scholar
  62. [62]
    Temperli P, Ghika J, Villemure JG, Burkhard PR, Bogousslavsky J, Vingerhoets FJG. How do parkinsonian signs return after discontinuation of subthalamic DBS? Neurology 2003, 60: 78–81.PubMedGoogle Scholar
  63. [63]
    Robichaud JA, Pfann KD, Comella CL, Corcos DM. Effect of medication on EMG patterns in individuals with Parkinson’s disease. Mov Disord 2002, 17: 950–960.PubMedCrossRefGoogle Scholar
  64. [64]
    Vaillancourt DE, Prodoehl J, Metman LV, Bakay RA, Corcos DM. Effects of deep brain stimulation and medication on bradykinesia and muscle activation in Parkinson’s disease. Brain 2004, 127: 491–504.PubMedCrossRefGoogle Scholar
  65. [65]
    Powell D, Hanson N, Threlkeld AJ, Fang X, Xia R. Enhancement of parkinsonian rigidity with contralateral hand activation. Clin Neurophysiol 2011, 122: 1595–1601.PubMedCrossRefGoogle Scholar
  66. [66]
    Shapiro MB, Vaillancourt DE, Sturman MM, Metman LV, Bakay RAE, Corcos DM. Effects of STN DBS on rigidity in Parkinson’s disease. IEEE Trans Neural Syst Rehabil Eng 2007, 15: 173–181.PubMedCrossRefGoogle Scholar
  67. [67]
    Xia R, Markopoulou K, Puumala SE, Rymer WZ. A comparison of the effects of imposed extension and flexion movements on Parkinsonian rigidity. Clin Neurophysiol 2006, 117: 2302–2307.PubMedCrossRefGoogle Scholar
  68. [68]
    Xia R, Sun J, Threlkeld AJ. Analysis of interactive effect of stretch reflex and shortening reaction on rigidity in Parkinson’s disease. Clin Neurophysiol 2009, 120: 1400–1407.PubMedCrossRefGoogle Scholar
  69. [69]
    Xia R. Physiological and biomechanical analyses of rigidity in Parkinson’s disease. In: Rana A (Eds.). Etiology and Pathophysiology of Parkinson’s Disease. Vienna, Austria: InTech, 2011: 485–506.Google Scholar
  70. [70]
    Kim MH, Cha KS, Kim HJ, Kim JS. Bilateral selective internal mammary artery angiography via right radial approach: clinical experience with newly designed Yumiko catheter. Catheter Cardiovasc Interv 2001, 54: 19–24.PubMedCrossRefGoogle Scholar
  71. [71]
    Morrison S, Kerr G, Silburn P. Bilateral tremor relations in Parkinson’s disease: Effects of mechanical coupling and medication. Parkinsonism Relat Disord 2008, 14: 298–308.PubMedCrossRefGoogle Scholar
  72. [72]
    Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov Disord 2008, 23: 1428–1434.PubMedCrossRefGoogle Scholar
  73. [73]
    Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2008, 23: 631–640.PubMedCrossRefGoogle Scholar
  74. [74]
    Protas EJ, Mitchell K, Williams A, Qureshy H, Caroline K, Lai EC. Gait and step training to reduce falls in Parkinson’s disease. NeuroRehabilitation 2005, 20: 183–190.PubMedGoogle Scholar
  75. [75]
    Nieuwboer A, Kwakkel G, Rochester L, Jones D, van Wegen E, Willems AM, et al. Cueing training in the home improves gaitrelated mobility in Parkinson’s disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007, 78: 134–140.PubMedCrossRefGoogle Scholar
  76. [76]
    Miyai I, Fujimoto Y, Yamamoto H, Ueda Y, Saito T, Nozaki S, et al. Long-term effect of body weight-supported treadmill training in Parkinson’s disease: a randomized controlled trial. Arch Phys Med Rehabil 2002, 83: 1370–1373.PubMedCrossRefGoogle Scholar
  77. [77]
    Scandalis TA, Bosak A, Berliner JC, Helman LL, Wells MR. Resistance training and gait function in patients with Parkinson’s disease. Am J Phys Med Rehabil 2001, 80: 38–43; quiz 44-36.PubMedCrossRefGoogle Scholar
  78. [78]
    Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection Trials in Parkinson’s Disease: Systematic Review. Mov Disord 2009, 24: 647–654.PubMedCrossRefGoogle Scholar
  79. [79]
    Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 1999, 56: 529–535.Google Scholar
  80. [80]
    Olanow CW, Schapira AHV, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, et al. TCH346 as a neuroprotective drug in Parkinson”s disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006, 5: 1013–1020.PubMedCrossRefGoogle Scholar
  81. [81]
    Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004, 1: 139–154.PubMedCrossRefGoogle Scholar
  82. [82]
    Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003, 54: 93–101.PubMedCrossRefGoogle Scholar
  83. [83]
    Olanow CW. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology 2009, 72: S59–64.PubMedCrossRefGoogle Scholar
  84. [84]
    Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (The ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008, 23: 2194–2201.PubMedCrossRefGoogle Scholar
  85. [85]
    Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009, 361: 1268–1278.PubMedCrossRefGoogle Scholar
  86. [86]
    Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Exp Neurol 2004, 187: 455–459.PubMedCrossRefGoogle Scholar
  87. [87]
    Mandel S, Weinreb O, Amit T, Youdim MB. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 2005, 48: 379–387.PubMedCrossRefGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Physical Therapy, School of Pharmacy and Health ProfessionsCreighton UniversityOmahaUSA
  2. 2.Department of Electrical and Computer Engineering and Department of BioengineeringUniversity of PittsburghPittsburghUSA

Personalised recommendations